PART I. FINANCIAL INFORMATION [Item 1. Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of operations, and cash flows [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet as of June 30, 2020, shows total assets decreased to **$145.5 million**, primarily due to reduced cash Condensed Consolidated Balance Sheet Highlights (in millions) | Account | June 30, 2020 | December 31, 2019 | | :--- | :--- | :--- | | Cash and cash equivalents | $25.0 | $55.0 | | Total current assets | $120.1 | $139.6 | | Total assets | $145.5 | $157.3 | | Total current liabilities | $43.0 | $50.0 | | Total liabilities | $52.4 | $50.6 | | Total stockholders' equity | $93.1 | $106.7 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Revenues increased in Q2 and H1 2020, but net losses widened to **$9.3 million** and **$18.4 million** respectively Statement of Operations Summary (in millions, except per share data) | Metric | Q2 2020 | Q2 2019 | H1 2020 | H1 2019 | | :--- | :--- | :--- | :--- | :--- | | Revenues | $19.5 | $15.8 | $38.7 | $29.9 | | Loss from operations | $(9.5) | $(4.1) | $(19.1) | $(9.5) | | Net loss | $(9.3) | $(5.9) | $(18.4) | $(11.6) | | Net loss per share | $(0.29) | $(0.89) | $(0.58) | $(2.38) | [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities significantly increased to **$24.0 million** in H1 2020, leading to a **$30.0 million** decrease in cash Cash Flow Summary (in millions) | Activity | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | | :--- | :--- | :--- | | Net cash used in operating activities | $(24.0) | $(10.8) | | Net cash used in investing activities | $(7.7) | $(2.8) | | Net cash provided by financing activities | $1.6 | $157.2 | | Net change in cash and cash equivalents | $(30.0) | $143.5 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Notes detail accounting policies, business operations, significant customer concentration, revenue recognition, and stock-based compensation - The company's primary business is providing sequencing and data analysis services for cancer therapy development and population sequencing initiatives, with the majority of revenues coming from the latter[33](index=33&type=chunk) Significant Customer Concentration | Customer | % of Revenues (H1 2020) | % of Revenues (H1 2019) | % of A/R (June 30, 2020) | | :--- | :--- | :--- | :--- | | VA MVP | 76% | 56% | 17% | | Pfizer Inc. | * | 20% | 44% | *Less than 10% - As of June 30, 2020, the company had **$39.3 million** in contracted but not yet recognized revenues, which are expected to be recognized within the next nine months[77](index=77&type=chunk) - Total stock-based compensation expense for the six months ended June 30, 2020 was **$3.1 million**, an increase from **$2.3 million** in the prior-year period[120](index=120&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=28&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, highlighting **29%** revenue growth driven by VA MVP, rising costs, and COVID-19 impacts [Overview](index=28&type=section&id=Overview) Personalis, a cancer genomics company, provides molecular data services, with significant revenue from VA MVP, impacted by COVID-19 - The company's NeXT Platform is designed to provide comprehensive information on all **~20,000 human genes** to support biopharmaceutical customers[135](index=135&type=chunk) - The COVID-19 pandemic and related shelter-in-place orders have negatively impacted productivity, disrupted business operations, and slowed research and development activities. Several customers were delayed in sending samples during the second quarter[138](index=138&type=chunk) [Results of Operations](index=30&type=section&id=Results%20of%20Operations) H1 2020 revenues increased **29%** to **$38.7 million**, driven by VA MVP, but rising costs led to a **$19.1 million** operating loss Revenues by Customer Type (in millions) | Customer Type | H1 2020 | H1 2019 | % Change | | :--- | :--- | :--- | :--- | | VA MVP | $29.5 | $16.9 | 75% | | All other customers | $9.2 | $13.0 | (30)% | | **Total revenues** | **$38.7** | **$29.9** | **29%** | - Cost of revenues increased by **50%** in H1 2020, primarily due to a **$7.4 million** increase in production materials for higher VA MVP volumes and a **$1.1 million** increase in personnel-related costs[159](index=159&type=chunk) - Selling, general and administrative expenses increased by **55%** in H1 2020, driven by a **$3.3 million** increase in personnel costs to expand the commercial team and a **$1.9 million** increase in professional services related to being a public company[163](index=163&type=chunk) [Liquidity and Capital Resources](index=33&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2020, the company had **$105.2 million** in cash and investments, with **$24.0 million** net cash used in operations - The company held **$25.0 million** in cash and cash equivalents and **$80.2 million** in short-term investments as of June 30, 2020[168](index=168&type=chunk) - Net cash used in operating activities increased to **$24.0 million** in H1 2020 from **$10.8 million** in H1 2019[168](index=168&type=chunk)[174](index=174&type=chunk) - The company paid off its Growth Capital Loan in August 2019 and has had no outstanding debt since[172](index=172&type=chunk)[179](index=179&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=35&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is exempt from this disclosure requirement as it qualifies as a smaller reporting company - The company is exempt from this disclosure requirement as it qualifies as a smaller reporting company[189](index=189&type=chunk) [Controls and Procedures](index=35&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2020, with no material changes - Management concluded that as of June 30, 2020, the company's disclosure controls and procedures were effective[190](index=190&type=chunk) - There were no changes in internal control over financial reporting during the second quarter of 2020 that have materially affected, or are reasonably likely to materially affect, internal controls[191](index=191&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=36&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any legal proceedings that would materially affect its business - As of the report date, the company is not involved in any material legal proceedings[193](index=193&type=chunk) [Risk Factors](index=36&type=section&id=Item%201A.%20Risk%20Factors) This section outlines significant risks, including net losses, customer concentration, competition, regulatory changes, and supplier reliance [Risks Related to Our Business and Strategy](index=36&type=section&id=Risks%20Related%20to%20Our%20Business%20and%20Strategy) The company faces business risks including net losses, high customer concentration with VA MVP, COVID-19 disruptions, and sole supplier reliance - The company has a history of net losses, with a net loss of **$18.4 million** for the six months ended June 30, 2020, and an accumulated deficit of **$159.0 million**[195](index=195&type=chunk) - The company has substantial customer concentration, with the VA MVP accounting for **76%** of revenues in the first half of 2020. The loss of this customer would have a material adverse effect[209](index=209&type=chunk) - The COVID-19 pandemic poses a significant risk, with shelter-in-place orders having already disrupted operations, slowed R&D, and delayed customer sample shipments[200](index=200&type=chunk)[202](index=202&type=chunk) - The company relies on Illumina as the sole supplier for its sequencers and associated reagents, and any disruption in this supply chain could significantly impact laboratory operations[216](index=216&type=chunk) [Risks Related to Government Regulation](index=49&type=section&id=Risks%20Related%20to%20Government%20Regulation) The company faces regulatory risks from potential FDA regulation of LDTs as medical devices, and compliance with CLIA and state licensing - The FDA has historically exercised enforcement discretion for LDTs, but it may change this policy, which could require the company to seek premarket clearance or approval for its tests[269](index=269&type=chunk) - If the FDA were to regulate its tests as medical devices, the company could face a lengthy and costly 510(k) or PMA process, potentially delaying or halting sales[272](index=272&type=chunk)[274](index=274&type=chunk) - The company must comply with CLIA and various state licensing requirements. Failure to maintain these certifications and licenses could result in the inability to perform tests and lead to significant penalties[282](index=282&type=chunk)[283](index=283&type=chunk)[284](index=284&type=chunk) [Risks Related to Our Intellectual Property](index=57&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) The company's success depends on protecting its intellectual property, facing risks from infringement claims, patent law uncertainty, and trade secrets - The company may face intellectual property infringement claims from third parties, which could block its ability to perform tests or result in substantial expenses and diversion of resources[301](index=301&type=chunk) - Recent court decisions regarding the patentability of natural phenomena and laws of nature create uncertainty and may adversely affect the company's ability to obtain and enforce patents on its genetic diagnostic tests[310](index=310&type=chunk) - The company relies on trade secrets and confidentiality agreements to protect proprietary information, but these measures may not be adequate to prevent unauthorized disclosure or use by employees, collaborators, or competitors[325](index=325&type=chunk)[326](index=326&type=chunk) [Risks Related to Our Common Stock](index=66&type=section&id=Risks%20Related%20to%20Our%20Common%20Stock) Risks related to common stock include price volatility, insider control, potential future stock sales, no dividends, and reduced reporting as an EGC - The market price of the company's common stock may be volatile due to factors such as fluctuating operating results, analyst reports, and general market conditions[343](index=343&type=chunk) - Directors, executive officers, and major shareholders exercise significant influence over corporate matters, which could delay or prevent a change of control[348](index=348&type=chunk) - The company is an "emerging growth company" under the JOBS Act, allowing it to comply with reduced public company reporting requirements[368](index=368&type=chunk) - The company has never paid dividends and does not expect to in the foreseeable future, meaning investment returns are dependent on stock price appreciation[352](index=352&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=72&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) There has been no material change in the planned use of proceeds from the company's Initial Public Offering - There has been no material change in the planned use of proceeds from the company's IPO[377](index=377&type=chunk) [Defaults Upon Senior Securities](index=72&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - None[378](index=378&type=chunk) [Mine Safety Disclosures](index=72&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - None[379](index=379&type=chunk) [Other Information](index=72&type=section&id=Item%205.%20Other%20Information) The company reports no other information for this item - None[380](index=380&type=chunk) [Exhibits](index=73&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including amendments, plans, and certifications - The report includes several exhibits, such as an amendment to a lease, an amendment to an employment letter, the 2020 Inducement Plan, and required CEO/CFO certifications[385](index=385&type=chunk)

Personalis, Inc. (NASDAQ:PSNL) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants Caroline Corner – Westwicke ICR John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Subbu Nambi – Cowen & Company Kevin DeGeeter – Oppenheimer Operator Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Personalis Earnings Conference Call. At this time, all participant lines are in listen-only mode. After the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-5411038 (State or oth ...

Personalis, Inc. (NASDAQ:PSNL) Q4 2019 Earnings Conference Call March 25, 2020 5:00 PM ET Company Participants Caroline Corner - Westwicke ICR John West - President and CEO Aaron Tachibana - CFO Clinton Musil - Chief Business Officer Conference Call Participants Derik De Bruin - Bank of America Merrill Lynch Doug Schenkel - Cowen & Company Kevin DeGeeter - Oppenheimer Operator Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter 2019 Personalis Earnings Conference Call. At this ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38943 Personalis, Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 27-5411038 | | --- | --- | | (State or other jurisdic ...

Personalis, Inc. (NASDAQ:PSNL) Q3 2019 Earnings Conference Call November 13, 2019 5:00 PM ET Company Participants Caroline Corner - Westwicke John West - President & CEO Aaron Tachibana - CFO Clinton Musil - Chief Business Officer Conference Call Participants Yih-Ming Tu - Morgan Stanley Xiaoxiao Ma - Bank of America Doug Schenkel - Cowen & Company Kevin DeGeeter - Oppenheimer Operator Ladies and gentlemen, thank you for standing by and welcome to the Third Quarter 2019 Personalis Earnings Conference Call. ...

PART I. FINANCIAL INFORMATION [Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) Unaudited financial statements for the period ended September 30, 2019, reflect significant asset and equity growth post-IPO, despite increased revenues and a wider net loss [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of September 30, 2019, the balance sheet reflects substantial increases in cash and total assets, driven by IPO proceeds, alongside decreased liabilities and a significant shift to stockholders' equity surplus Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2019 | Dec 31, 2018 | Change | | :--- | :--- | :--- | :--- | | **Assets** | | | | | Cash and cash equivalents | $87,013 | $19,744 | +$67,269 | | Total current assets | $140,298 | $29,559 | +$110,739 | | Total assets | $159,691 | $41,670 | +$118,021 | | **Liabilities & Equity** | | | | | Total liabilities | $48,299 | $58,654 | -$10,355 | | Redeemable convertible preferred stock | $0 | $89,404 | -$89,404 | | Total stockholders' equity (deficit) | $111,392 | $(106,388) | +$217,780 | - In June 2019, the company completed its IPO, raising net proceeds of **$139.8 million** after deducting underwriting discounts, commissions, and offering expenses[33](index=33&type=chunk)[41](index=41&type=chunk) [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the three and nine months ended September 30, 2019, revenues significantly increased, but a substantial rise in operating expenses led to a wider net loss for both periods Condensed Consolidated Statements of Operations (in thousands) | Metric | Q3 2019 | Q3 2018 | 9 Months 2019 | 9 Months 2018 | | :--- | :--- | :--- | :--- | :--- | | Revenues | $17,153 | $11,654 | $47,053 | $24,617 | | Loss from operations | $(5,730) | $(1,751) | $(15,222) | $(10,622) | | Net loss | $(6,885) | $(3,641) | $(18,439) | $(16,331) | | Net loss per share | $(0.22) | $(1.19) | $(1.35) | $(5.33) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the nine months ended September 30, 2019, operating cash flow shifted to a significant use, investing activities increased, and substantial IPO proceeds from financing led to a net increase in cash Cash Flow Summary for Nine Months Ended Sep 30 (in thousands) | Cash Flow Activity | 2019 | 2018 | | :--- | :--- | :--- | | Net cash (used in) provided by operating activities | $(20,474) | $2,369 | | Net cash used in investing activities | $(46,731) | $(7,181) | | Net cash provided by (used in) financing activities | $134,477 | $(629) | | **Net increase (decrease) in cash** | **$67,269** | **$(5,442)** | - Financing activities were dominated by **$144.0 million** in proceeds from the IPO, net of underwriting discounts, and **$20.0 million** from borrowings, offset by **$25.0 million** in debt repayments and **$3.95 million** in IPO-related costs[29](index=29&type=chunk) [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The notes detail key accounting policies, single segment operations, significant customer concentration, the June 2019 IPO, preferred stock conversion, and the repayment of a **$20.0 million** loan resulting in a **$1.7 million** loss on debt extinguishment - The company operates as one reportable segment: the sale of sequencing and data analysis services[31](index=31&type=chunk) Significant Customer Revenue Concentration (as % of Total Revenues) | Customer | Q3 2019 | Q3 2018 | 9 Months 2019 | 9 Months 2018 | | :--- | :--- | :--- | :--- | :--- | | VA MVP | 75% | 56% | 63% | 51% | | Pfizer Inc. | 11% | 10% | 17% | * | - On August 14, 2019, the company repaid its Growth Capital Loan in its entirety, recognizing a **$1.7 million** loss on debt extinguishment[98](index=98&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes **91%** year-over-year revenue growth to increased VA MVP volume, noting significant increases in operating expenses, while liquidity was substantially strengthened by **$144.0 million** in net IPO proceeds Revenue Comparison (in millions) | Period | 2019 | 2018 | Increase | % Change | | :--- | :--- | :--- | :--- | :--- | | **Three Months Ended Sep 30** | $17.2 | $11.7 | $5.5 | 47% | | **Nine Months Ended Sep 30** | $47.0 | $24.6 | $22.5 | 91% | - The increase in revenues from the VA MVP was driven by a higher volume of samples tested, partially offset by lower prices per sample[147](index=147&type=chunk)[148](index=148&type=chunk) - Selling, general, and administrative expenses for the nine months ended Sep 30, 2019 increased by **$8.1 million (107%)** year-over-year, primarily due to a **$5.0 million** increase in personnel-related expenses and a **$2.4 million** increase in professional services related to public company costs[154](index=154&type=chunk) - The company closed its IPO on June 24, 2019, receiving net proceeds of **$144.0 million**. As of September 30, 2019, cash, cash equivalents, and marketable securities totaled **$127.3 million**[159](index=159&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=33&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate sensitivity on its **$127.3 million** in cash and marketable securities, with a **100 basis point** rate increase potentially causing a **$0.3 million** fair value decline, while foreign currency risk is minimal - The company's primary market risk is interest income sensitivity related to its cash, cash equivalents, and short-term marketable debt securities[189](index=189&type=chunk) - A hypothetical **100 basis point** increase in interest rates would lead to an estimated **$0.3 million** decline in the fair value of the company's marketable debt securities as of September 30, 2019[189](index=189&type=chunk) - Foreign currency risk is minimal as the majority of revenues are generated in the U.S., with an insignificant amount denominated in foreign currencies[190](index=190&type=chunk) [Controls and Procedures](index=33&type=section&id=Item%204.%20Controls%20and%20Procedures) As of September 30, 2019, management concluded disclosure controls were not effective due to an un-remediated material weakness in internal control over financial reporting, stemming from insufficient accounting staff and lack of proper segregation of duties, despite ongoing remediation efforts - Management identified a material weakness in internal controls due to a lack of sufficient full-time accounting staff with the requisite experience and technical knowledge for complex accounting and proper segregation of duties[191](index=191&type=chunk)[338](index=338&type=chunk) - As of September 30, 2019, the material weakness was not fully remediated, leading to the conclusion that disclosure controls and procedures were not effective[192](index=192&type=chunk) - Remediation efforts include hiring a new Chief Financial Officer in March 2019 and four additional accounting resources in Q2 and Q3 2019[193](index=193&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=34&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any legal proceedings that would have a material adverse effect on its business, financial condition, or operating results - As of the report date, the company is not involved in any material legal proceedings[198](index=198&type=chunk) [Risk Factors](index=34&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks including a history of net losses, high customer concentration, potential regulatory changes for LDTs, and an identified material weakness in internal controls - The company has a history of net losses, with an accumulated deficit of **$133.9 million** as of September 30, 2019, and expects to incur significant losses for the foreseeable future[200](index=200&type=chunk) - There is substantial customer concentration, with the VA MVP accounting for **75%** of revenues in Q3 2019. The loss of this customer would have a material adverse effect[214](index=214&type=chunk) - The company's tests are marketed as Laboratory Developed Tests (LDTs), which are currently subject to FDA enforcement discretion. A change in this policy could subject the tests to more onerous regulation, increasing costs and time to market[261](index=261&type=chunk) - A material weakness in internal controls over financial reporting was identified due to a lack of sufficient experienced accounting staff, which could result in a material misstatement of financial statements[337](index=337&type=chunk)[338](index=338&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=69&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company details the use of **$139.8 million** net proceeds from its June 2019 IPO, confirming no material change from the planned use described in its final prospectus - The company's IPO closed on June 24, 2019, yielding net proceeds of approximately **$139.8 million** after discounts and expenses[366](index=366&type=chunk) - There has been no material change in the planned use of IPO proceeds as described in the final prospectus[367](index=367&type=chunk) [Defaults Upon Senior Securities](index=69&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - None [Mine Safety Disclosures](index=69&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - None [Other Information](index=69&type=section&id=Item%205.%20Other%20Information) The company reports no other information for this item - None [Exhibits](index=70&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including officer certifications and XBRL data files - Lists exhibits filed with the report, including officer certifications (31.1, 31.2, 32.1, 32.2) and XBRL instance documents[372](index=372&type=chunk)

Personalis, Inc. (NASDAQ:PSNL) Q2 2019 Earnings Conference Call August 13, 2019 5:00 PM ET Company Participants Caroline Corner - IR John West - President & CEO Aaron Tachibana - CFO Clinton Musil - Chief Business Officer Richard Chen - Chief Scientific Officer Conference Call Participants David Lewis - Morgan Stanley Derik De Bruin - Bank of America Merrill Lynch Doug Schenkel - Cowen Kevin DeGeeter - Oppenheimer Operator Welcome to the Q2 2019 Personalis Earnings Conference Call. [Operator Instructions]. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-5411038 (State or othe ...